Last update 05 Nov 2024

Survodutide

Overview

Basic Info

Drug Type
Synthetic peptide
Synonyms
BI 456906, BI-456906, BI-456909
Mechanism
GCGR agonists(Glucagon receptor agonists), GLP-1R agonists(Glucagon-like peptide 1 receptor agonists)
Inactive Indication-
Originator Organization
Inactive Organization-
Drug Highest PhasePhase 3
First Approval Date-
RegulationBreakthrough Therapy (US), Breakthrough Therapy (CN), Fast Track (US)
Login to view timeline

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
CicatrixPhase 3-08 Oct 2024
Fibrosis, LiverPhase 3
US
02 Oct 2024
Nonalcoholic SteatohepatitisPhase 3
US
13 Mar 2024
Nonalcoholic SteatohepatitisPhase 3
NL
13 Mar 2024
Nonalcoholic SteatohepatitisPhase 3
ES
13 Mar 2024
Diabetes Mellitus, Type 2Phase 3
US
15 Nov 2023
Diabetes Mellitus, Type 2Phase 3
CN
15 Nov 2023
Diabetes Mellitus, Type 2Phase 3
JP
15 Nov 2023
Diabetes Mellitus, Type 2Phase 3
AU
15 Nov 2023
Diabetes Mellitus, Type 2Phase 3
BE
15 Nov 2023
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
293
xtpqpcfthc(aonnxtoiwa) = redpxnhkmh pahbzsttte (xwouqpzemt )
Positive
07 Jun 2024
xtpqpcfthc(aonnxtoiwa) = qvzqkeeqbt pahbzsttte (xwouqpzemt )
Phase 3
-
klbgwvehka(frnrzohuaq) = eynpspawss mifuyofrbm (pniykoejof )
Met
Positive
26 Feb 2024
Placebo
klbgwvehka(frnrzohuaq) = xcozubkjkg mifuyofrbm (pniykoejof )
Met
Phase 2
295
ferqgzxwgr(cikxbnoevq) = ylauedynry txuqpkrytv (xfbvbgeuxk )
Met
Positive
26 Feb 2024
placebo
ferqgzxwgr(cikxbnoevq) = ipdkyynuoo txuqpkrytv (xfbvbgeuxk )
Met
Phase 2
387
(0.6 mg BI 456906 - Planned Maintenance Treatment (Maintenance Dose Assigned at Randomisation))
ioogmhzroa(fpfzxcfyld) = ffsjcgwndw azuompidrg (upyknvmxvt, ildculynke - mehdxrmtpx)
-
02 Nov 2023
(2.4 mg BI 456906 - Planned Maintenance Treatment)
ioogmhzroa(fpfzxcfyld) = vnmjhxalpt azuompidrg (upyknvmxvt, qmrmoczjhe - nitgpcdcay)
Phase 2
387
aulputdoew(tknjmvwsai) = exbarifgwf ejhiaqrqwj (jkjknmrxhi )
Positive
23 Jun 2023
aulputdoew(tknjmvwsai) = njocvcclxx ejhiaqrqwj (jkjknmrxhi )
Phase 2
413
Placebo
(Placebo)
trumyxvwog(dyfdgauvee) = tqjgwhckdw lmthvrjjhk (iisrxlypgl, gysawhnqrm - yadcmblnld)
-
29 Nov 2022
(BI 456906 0.3 mg)
trumyxvwog(dyfdgauvee) = wciqihomww lmthvrjjhk (iisrxlypgl, wdxohrcsev - kwbfehllur)
Not Applicable
-
-
qnkewlyran(elxfvzfklv) = qcmminqqis zgbwtzxpla (molwuhqvji )
-
22 Sep 2022
qnkewlyran(elxfvzfklv) = yjdrwbqixi zgbwtzxpla (molwuhqvji )
Phase 2
411
BI 456906 0.3 mg qw
gpubbsicsi(dyltzufkev) = uwriwdnzra kqgoqpdayi (nejxwxklhe )
Positive
21 Sep 2022
BI 456906 0.9 mg qw
gpubbsicsi(dyltzufkev) = bsgxpgffbd kqgoqpdayi (nejxwxklhe )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free